Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application

Cancers

BjörnE. Wahlin¹  Anders Österborg¹  TomA. Mulder²  Marzia Palma² 

[1] Department of Hematology, Karolinska University Hospital, 171 76Stockholm, Sweden;Department of Oncology-Pathology, Karolinska Institutet, 171 76 Stockholm, Sweden;

关键词: B-cell lymphoma;    tumor microenvironment;    immune cells;    T cells;    PD-1;    PD-L1;    macrophages;    CD47;    Hodgkin lymphoma;   

DOI  :  10.3390/cancers11070915

来源: DOAJ

【 摘 要 】

In lymphomas of B-cell origin, cancer cells orchestrate an inflammatory microenvironment of immune and stromal cells that sustain the tumor cell survival and growth, known as a tumor microenvironment (TME). The features of the TME differ between the different lymphoma types, ranging from extremely inflammatory, such as in Hodgkin lymphoma, to anergic, leading to immune deficiency and susceptibility to infections, such as in chronic lymphocytic leukemia. Understanding the characteristic features of the TME as well as the interactions between cancer and TME cells has given insight into the pathogenesis of most lymphomas and contributed to identify novel therapeutic targets. Here, we summarize the preclinical data that contributed to clarifying the role of the immune cells in the TME of different types of lymphomas of B-cell origin, and explain how the understanding of the biological background has led to new clinical applications. Moreover, we provide an overview of the clinical results of trials that assessed the safety and efficacy of drugs directly targeting TME immune cells in lymphoma patients.

【 授权许可】

Unknown